Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026
Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Fineline Cube Apr 27, 2026
Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Fineline Cube Apr 24, 2026
Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Fineline Cube Apr 24, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

CSPC Pharmaceutical Receives FDA Clearance to Launch First-in-Class KAT6 Inhibitor SYH2095 Clinical Trial for Advanced Cancers

Fineline Cube Apr 27, 2026
Company Drug

Bristol-Myers Squibb and Pfizer Partner with Mark Cuban’s Cost Plus Drugs to Offer Eliquis at $345 for 30-Day Supply, Expanding Access to Blockbuster Anticoagulant

Fineline Cube Apr 27, 2026
Company Deals

Saizeng Medical Licenses TSHR Antibody to Yarrow for $1.4B in Graves’ Disease Deal

Fineline Cube Dec 16, 2025

Saizeng Medical Technology Co. Ltd, a subsidiary of Changchun High‑Tech Industry (Group) Co., Ltd. (SHE:...

Company Medical Device

Zhicheng’s TAVR Robotic System Enters NMPA Innovation Pathway

Fineline Cube Dec 16, 2025

Zhicheng Medical Technology (Jiaxing) Co., Ltd. announced that its self‑developed ReachTact Transcatheter Aortic Valve Replacement...

Company Drug

ENHERTU Wins FDA Approval as First-Line HER2 Breast Cancer Therapy

Fineline Cube Dec 16, 2025

Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN) announced that ENHERTU (fam-trastuzumab deruxtecan-nxki) in...

Policy / Regulatory

FDA Removes Key RWE Limitation, Allowing Drug and Device Submissions Without Individual Patient Data

Fineline Cube Dec 16, 2025

The U.S. Food and Drug Administration (FDA) announced a major policy shift to accept Real-World...

Company Drug

Sanofi’s Tolebrutinib Fails Phase 3 PPMS Endpoint, Halting Registration Plans

Fineline Cube Dec 16, 2025

Sanofi (NASDAQ: SNY) announced that the Phase 3 PERSEUS study (NCT04458051) of tolebrutinib in primary progressive...

Company Drug

Konruns Doses First Patient in Phase 2 Esophageal Cancer Trial for KC1036

Fineline Cube Dec 16, 2025

Konruns Pharmaceutical Co., Ltd. (SHA: 603590) announced first patient dosing in the Phase 2 KC1036‑COM‑01...

Company Drug

Johnson & Johnson’s TECVAYLI Gets FDA Priority Review for Myeloma Combo

Fineline Cube Dec 16, 2025

Johnson & Johnson (NYSE: JNJ) announced that the U.S. FDA selected the teclistamab MajesTEC‑3 supplemental...

Company Deals

uBriGene Partners with Circurna on circRNA Manufacturing for Global Trials

Fineline Cube Dec 16, 2025

uBriGene Biosciences International Co. announced a strategic partnership with Circurna, a biotechnology company developing next‑generation...

Company Deals

Dren Bio, Sanofi Forge $1.8B B‑Cell Therapy Deal with US Co‑Promote Option

Fineline Cube Dec 16, 2025

Dren Bio, Inc. announced a strategic collaboration with Sanofi (NASDAQ: SNY) to discover and develop...

Company Deals

Adaptive Licenses TCR Data to Pfizer in $890M Deal for Rheumatoid Arthritis

Fineline Cube Dec 16, 2025

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) announced two non‑exclusive agreements with Pfizer Inc. (NYSE: PFE) to...

Company Drug

Hengrui NMPA Approves Four Clinical Trials Advancing Oncology and Metabolic Pipeline

Fineline Cube Dec 15, 2025

Jiangsu Hengrui Pharmaceutical Co., Ltd (SHA: 600276, HKG: 1276) announced that China’s National Medical Products...

Company Drug

GSK’s Nucala Wins CHMP Nod for COPD in Europe

Fineline Cube Dec 15, 2025

UK biopharma GlaxoSmithKline plc (GSK, NYSE: GSK) announced that the European Medicines Agency’s Committee for...

Company Deals

Sobi Acquires Arthrosi for $1.5 Billion to Add Gout Drug to Portfolio

Fineline Cube Dec 15, 2025

Swedish Orphan Biovitrum AB (Sobi) (STO: SOBI) announced a definitive agreement to acquire Arthrosi Therapeutics,...

Company Drug

Novo Nordisk’s Wegovy 7.2mg Gets EMA Positive Opinion for Obesity

Fineline Cube Dec 15, 2025

Novo Nordisk A/S (NYSE: NVO) announced that the European Medicines Agency’s Committee for Medicinal Products...

Company Drug

Innovent’s Mazdutide Wins Macau Approval for Weight Management

Fineline Cube Dec 15, 2025

Innovent Biologics, Inc. (HKG: 1801) announced that mazdutide received marketing approval from Macau’s drug regulatory...

Company Deals

Kyinno Biotechnology Closes RMB 250M Series B for Bispecific Antibody Pipeline

Fineline Cube Dec 15, 2025

Kyinno Biotechnology, a China‑based biotech company, announced the completion of its Series B financing round...

Company Deals

Cellular Origins Raises $40M Series A Led by Johnson & Johnson for Cell Therapy Manufacturing

Fineline Cube Dec 15, 2025

Cellular Origins announced the completion of an over‑subscribed $40 million Series A financing round led by...

Company Drug

Akeso’s Cadonilimab Wins FDA Nod for Global Phase 3 Gastric Cancer Study

Fineline Cube Dec 15, 2025

Akeso Biopharma (HKG: 9926) announced that the U.S. FDA approved cadonilimab in combination with chemotherapy...

Policy / Regulatory

China Healthcare Fund Settlement Reform Targets 3% Ratio by 2028

Fineline Cube Dec 15, 2025

The National Healthcare Security Administration (NHSA) released a notice to optimize healthcare fund settlement management,...

Company Drug

Junshi Biosciences Wins FDA Nod for EGFR/HER3 Bispecific ADC in Solid Tumors

Fineline Cube Dec 15, 2025

Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced that the U.S. Food and...

Posts pagination

1 … 59 60 61 … 657

Recent updates

  • CSPC Pharmaceutical Receives FDA Clearance to Launch First-in-Class KAT6 Inhibitor SYH2095 Clinical Trial for Advanced Cancers
  • Bristol-Myers Squibb and Pfizer Partner with Mark Cuban’s Cost Plus Drugs to Offer Eliquis at $345 for 30-Day Supply, Expanding Access to Blockbuster Anticoagulant
  • Henlius Biotech Launches Phase II/III Trial in Australia for Triple Combination Therapy in Squamous NSCLC Featuring Novel Anti-EGFR Antibody Pimurutamab and Approved PD-1 Inhibitor HanSiZhuang
  • Novartis Secures WHO Pre-Qualification for Coartem Baby, First Antimalarial Specifically Designed for Newborns and Infants Under 5 kg
  • AstraZeneca Secures FDA Approval for Subcutaneous Saphnelo in Systemic Lupus Erythematosus After Addressing Supplemental Data Request
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CSPC Pharmaceutical Receives FDA Clearance to Launch First-in-Class KAT6 Inhibitor SYH2095 Clinical Trial for Advanced Cancers

Company Drug

Bristol-Myers Squibb and Pfizer Partner with Mark Cuban’s Cost Plus Drugs to Offer Eliquis at $345 for 30-Day Supply, Expanding Access to Blockbuster Anticoagulant

Company Drug

Henlius Biotech Launches Phase II/III Trial in Australia for Triple Combination Therapy in Squamous NSCLC Featuring Novel Anti-EGFR Antibody Pimurutamab and Approved PD-1 Inhibitor HanSiZhuang

Company Drug

Novartis Secures WHO Pre-Qualification for Coartem Baby, First Antimalarial Specifically Designed for Newborns and Infants Under 5 kg

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.